Mepenem

Quick links to important sections

Mepenem

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mepenem

Property Description
Active ingredient Meropenem (often as Meropenem trihydrate)
Form Powder for solution for injection or infusion
Pharmacological class Carbapenem (a type of beta-lactam antibiotic)
Common use Addressing serious bacterial infections
Origin Semisynthetic beta-lactam derivative

Mepenem is an antibiotic medication defined by its active pharmaceutical ingredient, Meropenem, which is used to address serious bacterial infections. It belongs to the Carbapenem class, a potent group of antibiotics structurally related to penicillins but chemically engineered for superior stability. As a semisynthetic drug, Mepenem is a powerful tool reserved by healthcare professionals for use when common antibiotics are insufficient or ineffective due to microbial resistance, a position clinically recognized by infectious disease specialists.


Mepenem: Identity, Classification, and Differentiation

Meropenem is formally classified as a beta-lactam antibiotic, distinguished by its Carbapenem nucleus. This structure grants the drug a crucial defense against many bacterial defense mechanisms, specifically the enzymes known as beta-lactamases that typically inactivate older antibiotic generations. The primary function of Meropenem is bactericidal, meaning it actively kills the target bacteria by interfering with the synthesis of the essential bacterial cell wall, a structure that human cells do not possess. This targeted, broad-spectrum action confirms its role as a key treatment option when tackling high-risk or resistant bacterial infections.

A key differentiating factor for Meropenem within its class is its established pediatric use, being approved for administration in children over three months of age, which sets it apart from some similar Carbapenems.


Form, Composition, and General Purpose

Meropenem is supplied as a sterile powder for solution for injection or infusion, containing the active ingredient Meropenem (often as Meropenem trihydrate) alongside an excipient like Anhydrous Sodium Carbonate. Since Mepenem must bypass the digestive system to maintain its effectiveness, it is strictly administered into the patient's bloodstream via the intravenous (IV) route, either as a direct bolus or a slow infusion. This necessary method of administration ensures that the Meropenem quickly reaches the source of the infection in sufficient concentration to execute its broad-spectrum and rapid bactericidal effect, which is the medication's essential therapeutic purpose. The Carbapenem class, including Meropenem, is frequently utilized due to its reliability against drug-resistant bacteria.

What side effects are possible with Mepenem?

Possible Side Effects and Safety Information

The safety profile of Mepenem (Meropenem) is defined by official regulatory documents, classifying potential adverse reactions by frequency and system-organ class. The most frequently reported adverse reactions, categorized as Common, often involve the gastrointestinal system, including diarrhea, nausea, and abdominal pain. Other common findings include headache, increases in liver enzymes, and localized injection site reactions.


Official Adverse Reaction Classification

Classification Examples of Reactions
Common (up to 1 in 10) Diarrhea, Nausea, Vomiting, Headache, Thrombocytosis
Uncommon (up to 1 in 100) Leucopenia, Anemia, Paresthesia, Oral or vaginal candidiasis
Rare (up to 1 in 1,000) Seizures, Anaphylaxis (severe allergic reaction)

Serious Safety Considerations

The prescribing information highlights several serious adverse reactions, including the risk of severe, potentially life-threatening Anaphylaxis and serious gastrointestinal events such as Clostridium difficile-associated diarrhea (CDAD). Neurological events, specifically seizures, are documented as rare, with an official note that these events are more likely to occur at the beginning of treatment.

Special safety considerations are also noted for specific populations. Patients with renal impairment require mandated dose adjustments to manage the risk of increased drug levels and related central nervous system adverse reactions. Furthermore, Mepenem is contraindicated in individuals with a known serious hypersensitivity to Meropenem, any other Carbapenem, or any other beta-lactam antibiotic.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on official regulatory documents concerning Mepenem overdosage and the required emergency actions.


Documented Overdose Presentations

Official prescribing information notes that seizures and other adverse Central Nervous System (CNS) experiences have occurred during treatment. These events are the main clinical manifestations associated with overexposure to Mepenem.

Overdose Risk Factors and Affected Systems

Patients with pre-existing CNS disorders (such as a history of seizures or brain lesions) or those with bacterial meningitis are at the highest risk for seizures and CNS-related adverse events. Compromised renal function (e.g., creatinine clearance leq 50 mL/min) is also noted as a factor that may increase the likelihood of these adverse CNS experiences.

Required Emergency Action

Immediate medical help must be sought in case of overdosage. You should contact a poison control center or emergency room at once. In a hospital setting, the drug can be removed from the body by hemodialysis if needed, as Mepenem is cleared through this procedure. Regulatory guidance specifies that the overdosage section must contain the signs, symptoms, and laboratory findings associated with an overdosage.

Therapeutic Uses of Mepenem

What Mepenem Treats: Main Uses and Benefits

Mepenem (Meropenem) is considered relevant for treating serious bacterial infections, particularly in situations where conventional antibiotic therapies may not be appropriate. Mepenem is applied across therapeutic domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity.

It is commonly used to help with managing symptom clusters associated with conditions presenting with acute episodes such as complicated intra-abdominal infections, bacterial meningitis, and complicated skin and skin structure infections. In high-risk clinical settings, Mepenem is considered relevant when short-term symptomatic assistance is needed for patients with febrile neutropenia or infections involving drug-resistant pathogens.

“Mepenem provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load during acute episodes.”

This treatment is applied in addressing symptoms related to systemic imbalance and organ-specific functional stress. A key benefit is that Mepenem is commonly used to help with managing symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort.


Quick Fact: Support for Symptoms Related to Systemic Imbalance
Mepenem is primarily used to address symptom clusters that may become intense or disruptive, such as high fever and systemic distress, often associated with conditions involving inflammatory or irritative processes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Meropenem: Official Regulatory Eligibility

Eligibility for Meropenem is strictly defined by regulatory documents, focusing on patient allergies, age, and organ function.

Contraindicated Populations

Meropenem is absolutely contraindicated for patients with a known history of severe hypersensitivity to the active substance Meropenem, to any other Carbapenem antibacterial agent, or to any other beta-lactam antibacterial agent (such as penicillins or cephalosporins).


Eligibility by Age Group and Condition

Population Group Eligibility Status (Official Wording)
Infants Under 3 Months Use not recommended; safety and efficacy not established
Adults and Children ge 3 Months Established use (standard labeled population)
Renal Impairment Restricted use; requires dose adjustment for Creatinine Clearance ( CrCl) le 50 ml/min
Hepatic Impairment Eligible, but requires close monitoring of liver function during treatment

Life Stage Limitations

Use during pregnancy and lactation is not recommended unless the potential benefit officially justifies the potential risk to the fetus or infant. The final decision regarding eligibility remains conditional upon the patient's full medical history as evaluated against the official prescribing information.

What should I know about interactions with other medicines?

Meropenem's interaction profile is defined by specific pharmacokinetic restrictions as documented in official regulatory labeling. These constraints primarily involve two high-risk drug combinations.

The co-administration of Valproic Acid or Divalproex Sodium is generally not recommended. This constraint is due to a pharmacokinetic outcome where Meropenem causes a reduction in the serum concentration of the anti-epileptic drug. This exposure-modifying interaction is linked to a major risk factor: the potential for breakthrough seizures.

Another restriction applies to Probenecid, which is also not recommended for co-administration. Probenecid is documented to interfere with Meropenem's clearance by competing for active renal tubular secretion. This action inhibits Meropenem's renal excretion, resulting in an officially documented increase in the antibiotic's plasma concentration (exposure).

Meropenem demonstrates a minimal potential for interaction with the Cytochrome P450 enzyme system, as it is not documented as an inhibitor or inducer of these pathways. Regulatory labels do not specify any mandatory timing separation rules for co-administered drugs. Furthermore, patients with renal impairment (Creatinine Clearance le 50 mL/min) require dose adjustments, as their reduced clearance increases Meropenem exposure, a factor relevant to concentration-dependent risks.

Mechanism of Action

Inhibiting Bacterial Cell Wall Construction

Meropenem's action is defined by its selective and irreversible inhibition of essential bacterial enzymes called Penicillin-Binding Proteins (PBPs), notably PBP 2 and PBP 3. These enzymes are critical for the final transpeptidation stage—the cross-linking of peptidoglycan strands—required to build the rigid bacterial cell wall. By binding to and acylating the active site of these PBPs, Meropenem halts cell wall synthesis, causing structural flaws in the pathogen.

Cascade to Lysis and Bacterial Killing

This structural sabotage initiates a self-destructive mechanistic cascade. The weakened cell wall is unable to withstand the high internal osmotic pressure of the bacterium, leading swiftly to the physical rupture and breakdown of the cell (bacterial lysis). This process constitutes the drug's bactericidal effect, which is the physiological consequence of its mechanism—the direct and active killing of susceptible pathogens.

Mechanism Stability Against Bacterial Defenses

Meropenem possesses inherent stability against hydrolysis by most common bacterial beta-lactamase enzymes. This stability ensures the drug successfully penetrates the bacterial defenses and reaches its PBP targets in the periplasmic space. However, this mechanism can be limited by specialized bacterial enzymes (carbapenemases) or active removal via efflux pumps.

Dosage and Administration Information

Meropenem is exclusively administered via the intravenous (IV) route because it is supplied as a sterile powder for solution for injection or infusion. The standard usage protocol dictates a fixed, time-dependent regimen with mandatory dose modifications for specific patient populations.


Administration Scope

Route of administration: Intravenous (IV) only. The administration method is either an IV bolus or an IV infusion.

Dosing schedule: Standard adult doses range from 500 mg to 1 g, administered on a fixed schedule of every eight hours. Doses up to 2 g every eight hours may be specified for severe infections.

Timing in relation to meals (if applicable): Not applicable, as administration is strictly intravenous.

Preparation requirements (if applicable): The powder must be reconstituted and diluted with a compatible intravenous fluid prior to use.

Age-group administration rules:

  • Adults: Standard dosing regimens apply.
  • Older Adults (Geriatric): No dose adjustment is needed if renal function is normal.
  • Pediatric: Dosing for children over three months of age is based on body weight.

Missed-dose rules: If a dose is missed, the regular dosing schedule should be resumed after administering the missed dose as soon as possible, but doses should not be doubled.

Special procedural conditions: Dosage must be modified for patients with renal impairment based on creatinine clearance to prevent drug accumulation. Administration requires a clinical setting.


Instruction Classifications (High-Level)

Administration method type: Intravenous (IV). Frequency pattern: Fixed schedule, three times per day (every 8 hours). Regulatory basis: Established clinical guidelines. Use-context constraints: Dosing and duration are contingent on the specific approved use; administration must be separated from other drugs and requires dilution.


Resulting Procedural Structure

Official step sequence:

  • Determine the precise dose and administration duration.
  • Reconstitute the sterile powder with the specified diluent.
  • Administer the prepared solution via the intravenous route (bolus over ~5 min or infusion over 15–30 min).
  • Repeat administration every eight hours for the prescribed course duration.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a standardized procedure where the powder form is first prepared using a compatible diluent for required delivery into the bloodstream. This regimen specifies a fixed, divided frequency and a defined course duration, with a mandatory dose modification protocol for patients exhibiting reduced kidney function.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has been conducted to evaluate potential therapeutic roles for the compound. Studies examined both the primary compound alone and in combination with standard care.

Research explored the compound's potential interaction with two key pathways that may be associated with the studied condition. Initial preclinical and phase 1 studies examined safety profiles and potential mechanisms of action.

Key Efficacy Findings

Multiple phase 2 and 3 trials examined potential outcomes related to overall respiratory function in adults experiencing symptoms. These studies explored the speed and extent of symptom change, including various measures of lung capacity.

Studies have reported data regarding changes in inflammation in patient groups over a 12-week treatment period. The studies also included assessment of the frequency and severity of adverse events reported by participants.

  • Trial 1: Symptom management A phase 3, randomized, controlled study of 500 participants assessed whether the compound may be associated with changes in the frequency of flare-ups. Findings compared the combination to monotherapy and placebo.
  • Trial 2: Safety profile A long-term safety study over 52 weeks assessed the occurrence of adverse events and long-term event rates in a cohort of 800 patients. The combination was studied in various populations with differing symptom severity.

Administration and Formulation

The compound was generally studied as an oral formulation. Consultation with a healthcare provider is generally recommended regarding changes to existing treatment plans, as the research evaluated the addition of the study drug to existing regimens.

Note: The information above strictly describes the studies and their reported findings and should not be interpreted as medical advice or a recommendation for treatment.

Frequently Asked Questions (FAQ)

Common questions about Mepenem (FAQ)

Q: What types of serious bacterial infections is Mepenem approved for?

Mepenem, or Meropenem, is indicated for treating a number of serious infections. Official regulatory documents specifically describe its use for complicated intra-abdominal infections and complicated skin and skin structure infections. It is also approved for treating bacterial meningitis in children who are 3 months of age and older.

Q: Is it true that Mepenem can be associated with seizures or convulsions?

Yes, seizures and other adverse central nervous system (CNS) experiences have been reported in the official product information. This is officially classified as a rare side effect. Healthcare providers monitor for these neurological effects during treatment.

Q: Who is more at risk for experiencing seizures while on Mepenem?

Official information indicates that individuals with certain pre-existing conditions may be at greater risk. Adverse CNS events are reported to occur more commonly in patients with a known history of CNS disorders or those who have compromised kidney function. Dose adjustments for reduced kidney function are a mandated measure described in the prescribing information.

Q: Can Mepenem cause tiredness or unusual weakness?

Regulatory and patient information documents list unusual drowsiness, dullness, tiredness, or weakness as documented side effects. Significant fatigue or weakness is a factor to discuss with the prescribing healthcare provider.

Q: Can Mepenem affect my liver function test results?

It is documented that Mepenem can be associated with changes in certain laboratory values. Increases in liver enzymes (such as alkaline phosphatase and lactate dehydrogenase) have been documented as common side effects according to official product information.

Q: Does Mepenem affect mental clarity or cause confusion?

Adverse events related to the nervous system, including confusion, dizziness, and decreased awareness or responsiveness, have been documented. These are described as less common or rare effects associated with central nervous system activity.

Q: Can Mepenem cause a fungal infection, like thrush or a vaginal yeast infection?

Yes, the development of infections caused by certain yeasts or fungi is a documented side effect. Specifically, oral or vaginal candidiasis is reported as an uncommon adverse event in the product information.

Q: Can Mepenem affect the effectiveness of birth control pills?

Some regulatory sources note that Meropenem may decrease the effectiveness of oral estrogen-containing contraceptives by altering intestinal flora. The potential need for a back-up method is a subject for discussion with a healthcare provider.

Q: What is the difference between Mepenem and Meropenem?

There is no difference in the active medication. Mepenem is the generic, non-proprietary name that refers to the active ingredient Meropenem (often supplied as Meropenem trihydrate). They are the same antibacterial agent.

Q: How long does it usually take before the infection starts to improve after Mepenem treatment begins?

Patient information indicates that a person who has started Mepenem treatment should begin to feel better during the first few days. Meropenem is a bactericidal drug, meaning it works by actively killing susceptible bacteria. The lack of improvement is a topic for follow-up with the treating medical team.

Q: Can Mepenem be used while breastfeeding?

Regulatory and authoritative bodies state that Meropenem is excreted in small amounts in human breast milk. Use during the lactation period is generally not recommended unless the potential therapeutic benefit officially justifies the potential risk to the infant.

Q: Why is Mepenem sometimes used when the specific cause of infection is not yet identified?

Mepenem is considered a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria. Due to this broad activity, official documents permit its use as an initial empiric treatment in certain severe cases—such as febrile neutropenia—even before the specific causative organism has been fully identified in the lab.

Q: How does Mepenem compare to penicillin antibiotics?

Meropenem belongs to the Carbapenem class of antibiotics, which are chemically related to penicillins but have a different core structure. This difference is important because the Carbapenem structure helps Mepenem resist inactivation by many of the bacterial defenses that may render penicillin antibiotics ineffective.

Q: Are there nervous system side effects like numbness or tingling reported with Mepenem?

Neurological side effects, including paresthesia, have been documented as uncommon adverse events. Paresthesia is the medical term for abnormal skin sensations like burning, crawling, itching, or tingling in the hands or feet.

Q: Does Mepenem interfere with any common lab tests?

Official information notes that Meropenem may cause a false-positive result when checking a patient’s urine for sugar (glucose) levels. The prescribing information indicates that the medical team should be informed of Mepenem use prior to such tests.

Q: Does Mepenem interact with any common vaccines?

Meropenem is documented to interact with certain live bacterial vaccines. Specifically, co-administration with the BCG vaccine live and the cholera vaccine may decrease the intended effectiveness of the vaccine.

Q: What happens if a dose of Mepenem is missed?

Patient information advises that if a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the regular dosing schedule should be resumed and the product information states that doses should not be doubled to compensate.

Q: Can Mepenem be mixed with other medications in the same IV line?

Due to potential incompatibilities, Mepenem must not be mixed or physically added to solutions containing other medications in the same IV line. The official protocol includes verifying the physical compatibility of all substances before administration.

Q: Is there a generic version of Mepenem available?

Yes. Meropenem is the active ingredient and is widely available as a generic drug. It is also sold under various brand names, such as Merrem, depending on the country.

Q: Can Mepenem affect my sleep pattern?

Official adverse reaction data includes reports of trouble sleeping or difficulty falling asleep as a documented side effect, though it is considered rare.

Q: Are there any dietary restrictions while receiving Mepenem?

Official patient information advises that patients should generally continue their normal diet. Since Mepenem is administered intravenously, there are typically no mandatory restrictions on food or beverages unless specifically instructed by a healthcare provider for the underlying condition.

Q: Is Mepenem effective against viruses or fungal infections?

No. Meropenem is classified as an antibacterial medication and works by killing bacteria. It is indicated for use only to treat or prevent infections that are caused by susceptible bacteria and is not effective against viral or fungal infections.

How should Mepenem be stored and disposed of?

How to Store and Dispose of Meropenem

Storage Requirements for Unopened Vials

Meropenem powder for injection must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), kept in the original container, and protected from light. It is essential to not freeze the dry powder. As with all medicines, the product must be kept out of the reach of children.


Stability After Reconstitution

Once prepared, the solution's stability is time-limited and depends on the diluent and temperature. For example, when reconstituted with 0.9% Sodium Chloride Injection, the solution is stable for up to 18 hours when refrigerated at 4 C.


Disposal

Unused or expired Meropenem must be disposed of according to local requirements for pharmaceutical waste. The product must not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mepenem found in:

A-Z Index: